ZNTL

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.

Wall Street analysts forecast ZNTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZNTL is 6.60 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Zentalis Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Zentalis Pharmaceuticals Inc. EPS for the last quarter amounts to -0.37 USD, decreased -33.93 % YoY.

Zentalis Pharmaceuticals Inc (ZNTL) has 166 emplpoyees as of December 16 2025.

Today ZNTL has the market capitalization of 101.15M USD.